H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
Literal federal measure citations: H.R.1
2025 · 2nd Quarter (Apr 1 - June 30)
BRISTOL-MYERS SQUIBB
Filed by CROSSROADS STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- CROSSROADS STRATEGIES, LLC
- Client
- BRISTOL-MYERS SQUIBB
- Filing UUID
- cd92fe16-1910-4589-aefb-3d0af18961e0
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act.
Literal federal measure citations: H.R.1
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP, supply chain, and tariffs.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Literal federal measure citations: S.891
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.